Immunotherapy has changed the treatment landscape for cancer patients; however, immune‐related adverse events, such as primary and secondary adrenal insufficiency, can be life threatening, with potential differences in population incidence. This letter to the editor reports a real‐world experience of Hispanic/Latino patients treated with immunotherapy and the incidence of adrenal insufficiency.